Novartis Eye Drug Doesn't Infringe Rival's IP, UK Court Says

Law360, New York (October 11, 2012, 5:59 PM EDT) -- An appeals court in the U.K. said Wednesday that Novartis Pharmaceuticals U.K. Ltd.'s vision-loss drug Lucentis did not infringe technology patented by AstraZeneca PLC's MedImmune Ltd. unit, upholding a lower court ruling that found the patents invalid.

The U.K. Court of Appeal determined that Novartis's sale of Lucentis — a treatment for an eye condition known as wet age-related macular degeneration, or AMD, that can lead to loss or a limitation of a person's ability to see straight ahead — did not infringe one of MedImmune's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.